Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Preclinical Development of an Actinium-225-Labeled Antibody Radio-Conjugate Directed Against CD45 for Targeted Conditioning and Radioimmunotherapy

Dale Ludwig, PhD BS, Ruth Bryan, Wojciech Dawicki, PhD, Eileen M Geoghegan, Qing Liang, PhD, Sandesh Seth, MS, MBA, Mamata Gokhale, Mark S. Berger, MD, Vijay Reddy, MD PhD, Ravendra Garg, Kevin Allen, PhD, Ekaterina Dadachova

Blood (2019) 134 (Supplement_1): 5601.

https://doi.org/10.1182/blood-2019-128678

Published: 2019

Journal Articles

Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 ( 225 Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Moshe Yair Levy, MD, Jae H. Park, MD, Farhad Ravandi, MD, Alexander E. Perl, MD, John M. Pagel, MD PhD, B. Douglas Smith, MD, Elihu H. Estey, MD, Hagop Kantarjian, MD, Dragan Cicic, MD, David A. Scheinberg, MD PhD

Blood (2016) 128 (22): 4050.

https://doi.org/10.1182/blood.V128.22.4050.4050

Published: 2016

Journal Articles

Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Farhad Ravandi, MD, John M. Pagel, MD PhD, Jae H. Park, MD, B. Douglas Smith, MD, Moshe Yair Levy, MD, Elihu H. Estey, MD, Alexander E. Perl, MD, Hagop Kantarjian, MD, Dennis Earle, Dragan Cicic, MD, David A. Scheinberg, MD PhD

Blood (2015) 126 (23): 3794.

https://doi.org/10.1182/blood.V126.23.3794.3794

Published: 2015

Journal Articles

Immunotherapeutic Targeting of EphA3

Sara Charmsaz, Kirrilee J Miller, Bryan W Day, PhD, Fares El-Ajeh, PhD, Varghese Palath, PhD, Geoff T Yarranton, PhD, Christopher R Bebbington, DPhil., Andrew M Scott, PhD, Martin Lackmann, PhD, Andrew W Boyd, MD PhD

Blood (2014) 124 (21): 3720.

https://doi.org/10.1182/blood.V124.21.3720.3720

Published: 2014

Journal Articles

Phase I Trial of Targeted Alpha-Particle Therapy Using Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) in Combination with Low-Dose Cytarabine (LDAC) for Older Patients with Untreated Acute Myeloid Leukemia (AML)

Joseph G Jurcic, MD, Farhad Ravandi, MD, John M. Pagel, MD PhD, Jae H Park, MD, B. Douglas Smith, MD, Dan Douer, MD, Elihu H. Estey, MD, Hagop M. Kantarjian, MD, Richard L. Wahl, MD, Dennis Earle, Dragan Cicic, MD, David A. Scheinberg, MD PhD

Blood (2014) 124 (21): 5293.

https://doi.org/10.1182/blood.V124.21.5293.5293

Published: 2014

Journal Articles

Astatine-211 Conjugated To Anti-CD20 Monoclonal Antibody Eliminates B-Cell Lymphoma In a Mouse Model

Damian J. Green, MD, Mazyar Shadman, MD, MPH, Shani L. Frayo, BS, Jon C. Jones, Mark D. Hylarides, PhD, Aimee L. Kenoyer, BS, D. Scott Wilbur, PhD, Donald K. Hamlin, BS, Yukang Lin, PhD, Ajay K. Gopal, MD, Sofia H.L. Frost, PhD, Johnnie J. Orozco, MD, PhD, John M. Pagel, MD, PhD, Oliver W. Press, MD, PhD

Blood (2013) 122 (21): 4415.

https://doi.org/10.1182/blood.V122.21.4415.4415

Published: 2013

Journal Articles

Phase I Trial Of The Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) In Combination With Low-Dose Cytarabine (LDAC) For Older Patients With Untreated Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Farhad Ravandi, MD, John M. Pagel, MD, PhD, Jae H Park, MD, Dan Douer, MD, Elihu H. Estey, MD, Hagop M Kantarjian, MD, Dragan Cicic, MD, David A. Scheinberg, MD, PhD

Blood (2013) 122 (21): 1460.

https://doi.org/10.1182/blood.V122.21.1460.1460

Published: 2013

Journal Articles

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Todd L. Rosenblat, MD, Michael R. McDevitt, PhD, Neeta Pandit-Taskar, MD, Jorge A. Carrasquillo, MD, Suzanne M. Chanel, RN, Kevin Zikaras, BS, Mark G. Frattini, MD, PhD, Peter G. Maslak, M.D., Dragan Cicic, MD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD

Blood (2011) 118 (21): 768.

https://doi.org/10.1182/blood.V118.21.768.768

Published: 2011

Journal Articles

Vascular Endothelial-Cadherin Targeted Alpha-Particle Mediated Vascular Killing and Remodeling Augments Subsequent Chemotherapeutic Efficacy.

Freddy E Escorcia, Erik Henke, PhD, Michael R. McDevitt, PhD, Carlos Villa, Peter Smith-Jones, PhD, Ronald Blasberg, MD, Robert Benezra, David A. Scheinberg, MD, PhD

Blood (2009) 114 (22): 3054.

https://doi.org/10.1182/blood.V114.22.3054.3054

Published: 2009

Journal Articles

Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213 ( 213 Bi)-Labeled-HuM195 (Lintuzumab) for Acute Myeloid Leukemia (AML)

Todd Rosenblat, MD, MS, Michael R. McDevitt, PhD, Deborah A. Mulford, MD, Neeta Pandit-Taskar, MD, Mark A. Weiss, MD, Mark L. Heaney, MD, PhD, Suzanne Chanel, RN, Alfred Morgenstern, PhD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD, Joseph G. Jurcic, MD

Blood (2008) 112 (11): 2983.

https://doi.org/10.1182/blood.V112.11.2983.2983

Published: 2008

Journal Articles

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-HuM195 (Anti-CD33) in Acute Myeloid Leukemia (AML).

Todd L. Rosenblat, MD, Michael R. McDevitt, PhD, Neeta Pandit-Taskar, MD, Jorge A. Carrasquillo, MD, Suzanne Chanel, RN, Mark G. Frattini, MD, PhD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD, Joseph G. Jurcic, MD

Blood (2007) 110 (11): 910.

https://doi.org/10.1182/blood.V110.11.910.910

Published: 2007

Journal Articles

Targeted Alpha Radiation and Gamma Rays Induce Distinct and Mutation Status Specific Transcriptional Responses in Human Leukemic Lymphocytes.

Simona Martin, PhD, Ralf Kronenwett, PhD, Katia Vandenbulcke, Fritz Offner, Prof, Slawomir Kliszewski, Christos Apostolidis, PhD, Alfred Morgenstern, PhD, Ulrich Steidl, PhD, Sascha Raschke, Frank Neumann, PhD, Jan Philippe, PhD, Guido Slegers, PhD, Rainer Haas

Blood (2004) 104 (11): 4372.

https://doi.org/10.1182/blood.V104.11.4372.4372

Published: 2004

Journal Articles

Additional alpha applications

David A. Scheinberg

Blood (2003) 101 (12): 4651.

https://doi.org/10.1182/blood-2003-04-1079

Published: 2003

NARROW

Preclinical Development of an Actinium-225-Labeled Antibody Radio-Conjugate Directed Against CD45 for Targeted Conditioning and Radioimmunotherapy

Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 ( 225 Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)

Immunotherapeutic Targeting of EphA3

Phase I Trial of Targeted Alpha-Particle Therapy Using Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) in Combination with Low-Dose Cytarabine (LDAC) for Older Patients with Untreated Acute Myeloid Leukemia (AML)

Astatine-211 Conjugated To Anti-CD20 Monoclonal Antibody Eliminates B-Cell Lymphoma In a Mouse Model

Phase I Trial Of The Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) In Combination With Low-Dose Cytarabine (LDAC) For Older Patients With Untreated Acute Myeloid Leukemia (AML)

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)

Vascular Endothelial-Cadherin Targeted Alpha-Particle Mediated Vascular Killing and Remodeling Augments Subsequent Chemotherapeutic Efficacy.

Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213 ( 213 Bi)-Labeled-HuM195 (Lintuzumab) for Acute Myeloid Leukemia (AML)

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-HuM195 (Anti-CD33) in Acute Myeloid Leukemia (AML).

Targeted Alpha Radiation and Gamma Rays Induce Distinct and Mutation Status Specific Transcriptional Responses in Human Leukemic Lymphocytes.

Additional alpha applications

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only